Official Title: An Intervention to Reduce Phthalate and Bisphenol Exposure During 
the Critical Period of Minipuberty  
NCT Number : [STUDY_ID_REMOVED]
Study Number: 23-[ZIP_CODE] 
Document Type: Study Protocol and Statistical Analysis Plan
Date of the 
Document:   December 13, 2023 
Study Number: s23-[ZIP_CODE]
Version Date: 12/06/2023
Page i
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226725]: 18 July 2022An intervention to reduce phthalate and bisphenol exposure during 
the critical period of minipuberty
Principal Investigator: [INVESTIGATOR_226707] G. Kahn, PhD, MPH
Assistant Professor, Department of Pediatrics, NYU Grossman 
School of Medicine
[ADDRESS_272507], Room 811, [LOCATION_001], NY [ZIP_CODE]
[EMAIL_4475]
[PHONE_4794]
NYULH Study Number: s23-[ZIP_CODE]
Initial version: 5/2/2023
Amended: 12/06/2023
Amended: [date]

Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023  
CONFIDENTIAL
This material is the property of the NYU School of Medicine and Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226726] (45 CFR Part 46), any 
other applicable US government research regulations, and institutional research policies and procedures. The Principal Investigator [INVESTIGATOR_226708], or changes to the protocol will take place without prior agreement from the sponsor and documented approval from the 
Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the 
conduct of this study have completed Human Subjects Protection Training.  
  
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 2  
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 2022Table of Contents 
 
PROTOCOL SUMMARY .............................................................................................................................. 6  
SCHEMATIC OF STUDY DESIGN  .............................................................................................................. 8  
KEY ROLES ................................................................................................................................................. 9  
1 INTRODUCTION, BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE.....................10
1.1 BACKGROUND INFORMATION AND RELEVANT LITERATURE  ............................................................................................................................... 10  
1.2 RATIONALE  ................................................................................................................................................................................................... 11  
1.3 P OTENTIAL RISKS &BENEFITS.......................................................................................................................................................................11
1.3.1 Known Potential Risks ............................................................................................................................................................................ 11  
1.3.2 Known Potential Benefits ....................................................................................................................................................................... 11  
2 OBJECTIVES AND PURPOSE.........................................................................................................12
2.1 PRIMARY OBJECTIVE  ..................................................................................................................................................................................... 12  
2.2 SECONDARY OBJECTIVES  .............................................................................................................................................................................. 12  
3 STUDY DESIGN AND ENDPOINTS..................................................................................................12
3.1 DESCRIPTION OF STUDY DESIGN ................................................................................................................................................................... 12  
3.2 STUDY ENDPOINTS ........................................................................................................................................................................................ 12  
3.2.1 Primary Study Endpoints........................................................................................................................................................................12
3.2.2 Secondary Study Endpoints ................................................................................................................................................................... 12  
3.2.3 Exploratory Endpoints............................................................................................................................................................................13
4 STUDY ENROLLMENT AND WITHDRAWAL .................................................................................. 13  
4.1 I NCLUSION CRITERIA.....................................................................................................................................................................................13
4.2 E XCLUSION CRITERIA....................................................................................................................................................................................13
4.3 V ULNERABLE SUBJECTS ................................................................................................................................................................................13
4.4 S TRATEGIES FOR RECRUITMENT AND RETENTION ...........................................................................................................................................14
4.4.1 Use of DataCore/Epic Information for Recruitment Purposes ...............................................................................................................15
4.5 D URATION OF STUDY PARTICIPATION .............................................................................................................................................................15
4.6 T OTAL NUMBER OF PARTICIPANTS AND SITES.................................................................................................................................................15
4.7 P ARTICIPANT WITHDRAWAL OR TERMINATION .................................................................................................................................................15
4.7.1 Reasons for Withdrawal or Termination.................................................................................................................................................15
4.7.2 Handling of Participant Withdrawals or Termination..............................................................................................................................15
4.7.3 Premature Termination or Suspension of Study....................................................................................................................................15
5 BEHAVIORAL/SOCIAL INTERVENTION.........................................................................................16
5.1 S TUDY INTERVENTION DESCRIPTION ..............................................................................................................................................................16
5.1.1 Administration of Intervention.................................................................................................................................................................16
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 3  
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July [ZIP_CODE] STUDY PROCEDURES AND SCHEDULE.......................................................................................16
6.1 S TUDY PROCEDURES /EVALUATIONS ..............................................................................................................................................................[ADDRESS_272508] of Care Study Procedures......................................................................................................................................................17
6.2 S TUDY SPECIFIC BIOSPECIMENS ....................................................................................................................................................................17
6.2.1 Specimen Collection Procedures ........................................................................................................................................................... 17  
6.2.2 Specimen Preparation, Handling, and Storage......................................................................................................................................17
6.2.3 Specimen Shipment ............................................................................................................................................................................... 18  
6.2.4 Laboratory Evaluations ........................................................................................................................................................................... 18  
6.3 S TUDY SCHEDULE .........................................................................................................................................................................................18
6.3.1 Screening ............................................................................................................................................................................................... 18  
6.3.2 Enrollment/Baseline ...............................................................................................................................................................................18
6.3.3 Phone Call - 2 Weeks After Delivery......................................................................................................................................................19
6.3.4 Phone Call - 6 Weeks After Delivery ...................................................................................................................................................... 19  
6.3.5 Study Visit...............................................................................................................................................................................................19
6.3.6 Withdrawal Visit......................................................................................................................................................................................19
6.3.7 Unscheduled Visit ................................................................................................................................................................................... 19  
7 SAFETY AND ADVERSE EVENTS...................................................................................................19
7.1 Definition of Adverse Events (AE)..........................................................................................................................................................19
7.1.1 Definition of Serious Adverse Events (SAE) .......................................................................................................................................... 20  
7.1.2 Definition of Unanticipated Problems (UP).............................................................................................................................................20
7.2 C LASSIFICATION OF AN ADVERSE EVENT........................................................................................................................................................20
7.2.1 Severity of Event .................................................................................................................................................................................... 20  
7.2.2 Relationship to Study Intervention..........................................................................................................................................................21
7.2.3 Expectedness.........................................................................................................................................................................................21
7.3 T IME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW-UP.....................................................................................................21
7.4 R EPORTING PROCEDURES –NOTIFYING THE IRB...........................................................................................................................................22
7.4.1 Adverse Event Reporting.......................................................................................................................................................................22
7.4.2 Serious Adverse Event Reporting..........................................................................................................................................................22
7.4.3 Unanticipated Problem Reporting..........................................................................................................................................................22
7.4.4 Reporting of Pregnancy..........................................................................................................................................................................23
7.5 R EPORTING PROCEDURES –NOTIFYING THE STUDY SPONSOR.......................................................................................................................23
7.6 R EPORTING PROCEDURES –PARTICIPATING INVESTIGATORS ..........................................................................................................................23
8 STUDY OVERSIGHT.........................................................................................................................23
9 STATISTICAL CONSIDERATIONS..................................................................................................24
9.1 S TATISTICAL AND ANALYTICAL PLANS............................................................................................................................................................24
9.2 S TATISTICAL HYPOTHESES ............................................................................................................................................................................24
9.3 A NALYSIS DATASETS.....................................................................................................................................................................................24
9.4 D ESCRIPTION OF STATISTICAL METHODS.......................................................................................................................................................24
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 4  
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July [ZIP_CODE].4.1 Analysis of the Primary Efficacy Endpoint..............................................................................................................................................24
9.4.2 Analysis of the Secondary Endpoints.....................................................................................................................................................24
9.4.3 Safety Analyses ...................................................................................................................................................................................... 24  
9.4.4 Adherence and Retention Analyses.......................................................................................................................................................24
9.4.5 Baseline Descriptive Statistics...............................................................................................................................................................25
9.4.6 Enrollment/Randomization/Masking Procedures ................................................................................................................................... 25  
9.4.7 Evaluation of Success of Blinding..........................................................................................................................................................25
9.4.8 Breaking the Study Blind/Participant Code ............................................................................................................................................ 25  
10 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS.................................25
11 QUALITY ASSURANCE AND QUALITY CONTROL.......................................................................26
12 ETHICS/PROTECTION OF HUMAN SUBJECTS ............................................................................. [ADDRESS_272509] POLICY..................................................................................................32
17 REFERENCES...................................................................................................................................32
18 ATTACHMENTS................................................................................................................................33
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 5  
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: [ADDRESS_272510] of Abbreviations
 
AE Adverse Event/Adverse Experience
CFR Code of Federal Regulations
CRF Case Report Form
CSOC Clinical Study Oversight Committee
DCC Data Coordinating Center
DHHS Department of Health and Human Services
DSMB Data and Safety Monitoring Board
EDC Endocrine-Disrupting Chemical
EMR Medical Record Number 
FFR Federal Financial Report
FWA Federal wide Assurance
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act
ICF Informed Consent Form
IRB Institutional Review Board
LOD Limit of Detection
ISM Independent Safety Monitor
MOP Manual of Procedures
MRN Medical Record Number 
N Number (typi[INVESTIGATOR_33891])
NIH National Institutes of Health
NYU CHES [LOCATION_001] University Children’s Health and Environment Study
OHRP Office for Human Research Protections
OHSR Office of Human Subjects Research
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 6  
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 2022PI [INVESTIGATOR_226709]/Serious Adverse Experience 
SOP Standard Operating Procedure
US [LOCATION_002]
 
 
 
 
Protocol Summary
 
Title An intervention to reduce phthalate and bisphenol exposure during the critical 
period of minipuberty
Short Title Diaper Study  
Brief SummaryPhthalates and bisphenols have been detected in a range of infant care 
products. This pi[INVESTIGATOR_226710]’ body burden 
of phthalates and bisphenols. We will recruit 10 participants from the ongoing 
NYU Children’s Health and Development Study (CHES) cohort study who are 
>=37 weeks gestation or <[ADDRESS_272511] or next three months of their 
children’s lives. Toward the end of the intervention, we will collect maternal 
breast milk and infant urine, and assay samples for phthalate metabolite and 
bisphenol concentrations. 
Phase N/A
ObjectivesAim 1: To assess the feasibility of an intervention designed to reduce infant 
phthalate and bisphenol exposure
Aim 2 (exploratory): To compare urinary phthalate and bisphenol exposure 
levels in the intervention and non-intervention groups, as well as between 
mothers and children in the control group.
Methodology Open-label randomized controlled trial
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 7  
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: [ADDRESS_272512] for phthalate metabolite and bisphenol 
concentrations  
Study Duration1 year (allows for 6 months of data collection among 10 participants and 6 
months of data analysis).
Participant Duration 3 months 
PopulationWe will recruit 10 participants who are already enrolled in the NYU CHES 
study at the Brooklyn campus. Eligible participants will be >=37 weeks 
gestation or <6 months postpartum, carrying a singleton fetus or with a 
singleton infant, and intending to breastfeed or breastfeeding.
Study Site NYULH-Brooklyn
Number of participants 10 participants
Description of Study 
Intervention/Procedure Half of the participants will be randomly assigned to the intervention group 
and will receive a three-month supply of phthalate- and bisphenol-free baby 
[CONTACT_133294] (e.g., wipes, diaper cream) and a subscription to a cloth diaper 
service.
Reference Therapy Half of the participants will be randomly assigned to the control group and 
provided with a three-month supply of conventional disposable diapers (e.g., 
Huggies or Pampers) and baby [CONTACT_133294] (e.g., wipes, diaper cream).
Key ProceduresThree-month adherence to diaper assignment and one-time infant urine 
collection and maternal breast milk collection. 
Statistical AnalysisOur primary aim is to assess the feasibility of the intervention; the project is 
not adequately powered to detect statistically significant differences between 
groups. However, we will compare distributions of chemicals between the two 
infant groups to assess the effectiveness of the intervention and also 
between mothers and children from the control group to assess the relative 
prevalence of particular bisphenols or phthalates in diet (reflected in maternal 
breast milk concentrations) vs. baby [CONTACT_133294] (reflected in infant urinary 
concentrations).
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 9  
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 2022 
 
Key Roles
 
Linda G. Kahn, PhD, MPH  (Principal Investigator) 
Assistant Professor, Department of Pediatrics, NYU Grossman School of Medicine 
[ADDRESS_272513], Room 811, [LOCATION_001], NY [ZIP_CODE] 
[EMAIL_4475] 
([PHONE_4795] 
 
Leonardo Trasande, MD (Sub-Investigator) 
Pediatrics, Environmental Medicine & Population Health, NYU Grossman School of Medicine 
Director and PI [INVESTIGATOR_226711]   
[ADDRESS_272514] floor, [LOCATION_001], NY [ZIP_CODE] 
[EMAIL_4476] 
 ([PHONE_4796] 
 
Sunmi Lee, MS (Sub-investigator) 
Research Scientist, Lab Manager, Department of Pediatrics, Division of Environmental Pediatrics, NYU Grossman School of Medicine 
[ADDRESS_272515], [LOCATION_001], NY [ZIP_CODE] 
[EMAIL_4477] 
([PHONE_4797] 
(Analyze phthalate and bisphenol levels in urine and breast milk) 
 
Christian Villela Santos  (Sub-Investigator)  
Research Data Associate, Department of Pediatrics, Division of Environmental Pediatrics, NYU Grossman School of Medicine 
[ADDRESS_272516], [LOCATION_001], NY [ZIP_CODE]
[EMAIL_4478] 
([PHONE_4798] 
(Recruitment, consenting, project management, and data collection) 
 
Dimitri Abrahamsson, PhD (Study Team Member)  
Assistant Professor, Department of Pediatrics, NYU Grossman School of Medicine 
[ADDRESS_272517], [LOCATION_001], NY [ZIP_CODE] 
[EMAIL_4479] 
([PHONE_4799] 
(Assist in analysis of urine and breast milk) 
 
 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 10
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 2022 
1 Introduction, Background Information and Scientific Rationale
1.1 Background Information and Relevant Literature
 
In keepi[INVESTIGATOR_226712]’s fetal programming hypothesis,[ADDRESS_272518] been inconclusive, however,2,3with inconsistencies commonly attributed to varying approaches 
to exposure assessment and other methodological issues. An alternative explanation that has not been explored is the possibility that pregnancy 
may not be the only—or even the primary—critical period for early-life endocrine disruption. Minipuberty, a brief window during the first six months 
of life when sex hormones surge in sync with gonadal cell proliferation, may be a particularly vulnerable period for dysregulation of the 
hypothalamic-pi[INVESTIGATOR_2117]-gonadal axis by [CONTACT_226728]-disrupting chemicals (EDCs).[ADDRESS_272519] focused on prenatal exposure, including Niels Skakkebaek’s 
Testicular Dysgenesis Syndrome theory5and Germaine Buck-Louis’s companion Ovarian Dysgenesis Syndrome theory,6gestation is not the only 
critical period in the development of reproductive endocrine glands. Testicular Leydig and ovarian granulosa cells undergo three phases of 
maturation, culminating in sexual maturity. The first is mid-pregnancy, when Leydig cells proliferate in the fetal testis7and primordial follicles 
emerge in the fetal ovary.8The second is during minipuberty, when Leydig cells undergo another burst of proliferation and differentiation, and 
granulosa cells also proliferate as part of the postnatal surge in folliculogenesis.[ADDRESS_272520] 
negative consequences for the development of a variety of tissues and organs that are regulated by [CONTACT_226729], including brain, bone, 
adipocytes, and gonads.  
 
Little research has been done on potential causes and effects of endocrine disruption during minipuberty. The only study to date to examine 
associations between EDCs and sex hormones during minipuberty reported positive associations between urinary bisphenol A (BPA) and both 
estradiol and the estradiol:testosterone ratio in the first three months of life.10These results are consistent with BPA’s estrogenic profile; the study 
did not measure phthalates, which are more commonly anti-androgenic. Sex hormones in minipuberty, in turn, have been linked with child health 
outcomes. Nearly all of the research in this area has focused on neurodevelopment, demonstrating links between lower testosterone levels in 
male infants and compromised auditory processing and language development.11-15Sex hormones also affect metabolism. One small study that 
examined minipuberty sex hormone levels and adipose tissue development found that testosterone and luteinizing hormone were negatively 
associated with body mass index, and estradiol was positively associated with skinfold thicknesses in boys.16
 
This pi[INVESTIGATOR_226713]’ exposure to bisphenols and phthalates through common infant care products. If 
research continues to show child health consequences of bisphenol and phthalate exposure during minipuberty, these products could eventually 
be targeted for regulation. 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 11
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: [ADDRESS_272521] been detected in a range of infant care products, including diapers,17,18wipes, baby [CONTACT_226730], soaps, shampoos,19and plastic baby 
[CONTACT_226731].20Exposure is magnified by [CONTACT_211046]’ high surface-to-volume ratio and by [CONTACT_226732].21This pi[INVESTIGATOR_226714]’ body burden of phthalates and bisphenols. If successful, this protocol may be scaled up and eventually evidence may 
be used to inform regulation of chemicals contained in infant care products and educational outreach programs to protect children’s health.  
 
Aim 1: To assess the feasibility of an intervention designed to reduce infant phthalate and bisphenol exposure.  
H1: We will successfully recruit participants from within an existing cohort study and collect biosamples from participants and their children in a 
single follow-up study visit.  
 
Aim 2 (exploratory): To compare urinary phthalate metabolites and bisphenols between the intervention and non-intervention groups, as well as 
between mothers and children in the control group. 
H2: Chemical levels will be higher among infants in the control group vs. the intervention group. There will be no difference in average chemical 
concentrations between the two groups of mothers. Among controls, different chemicals will be present in breast milk vs. infant urine. 
 
1.3 Potential Risks & Benefits
1.3.[ADDRESS_272522] participants’ privacy by [CONTACT_226733] a code, and keepi[INVESTIGATOR_226715] a password-protected database accessible only to IRB-approved study personnel.   
 
There is no excess risk to participants associated with completing questionnaires. Participants may feel frustrated from answering questions. If 
that happens, participants are free to skip any questions they do not wish to answer.  
1.3.2 Known Potential Benefits 
Participants may gain the knowledge that they will be contributing to research that may improve our understanding of the relation between baby 
[CONTACT_133294], EDC exposure, and minipuberty.  
 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 12
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July [ZIP_CODE] Objectives and Purpose 
2.1 Primary Objective
The primary objective of this study is to assess the feasibility of an intervention designed to reduce infant phthalate and bisphenol exposure during 
the potential critical period of minipuberty. Specifically, we aim to evaluate the feasibility of an intervention that targets EDC exposure through 
randomly assigning participants to receive conventional diapers and baby [CONTACT_226734]- and bisphenol-free baby 
[CONTACT_226735] 3 months.  
2.2 Secondary Objectives  
The secondary and exploratory objective for this study is to compare urinary phthalate and bisphenol exposure levels in the intervention and non-
intervention groups, as well as between mothers and children in the control group  
 
3 Study Design and Endpoints 
3.1 Description of Study Design 
 This is a single-site pi[INVESTIGATOR_226716]-Brooklyn.  
 Participants will be recruited from the ongoing pregnancy/birth cohort study, NYU CHES study. 
 Participants will be randomly assigned to an intervention group (N=5) or a control group (N=5).  
 Participants will receive a 3-month supply of either disposable diapers and conventional baby [CONTACT_133294] (control group) or cloth diapers 
and phthalate- and bisphenol-free baby [CONTACT_133294] (intervention group) at no cost. 
 Participants will complete brief adherence surveys at three postnatal time points.  
 After [ADDRESS_272523] milk samples will be analyzed for phthalate metabolites and bisphenols in the NYU Human and Environmental 
Exposure Assessment Facility Core lab. 
3.2 Study Endpoints
3.2.1 Primary Study Endpoints
The primary endpoint, needed to fulfill Aim 1, is when the total number of participants (N=10) have used their assigned baby [CONTACT_226736] (maternal breast milk and infant urine) have been collected from all participants.  
3.2.2 Secondary Study Endpoints
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 13
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: [ADDRESS_272524] been analyzed for phthalate metabolites and bisphenols. 
3.2.3 Exploratory Endpoints 
 
N/A 
 
[ADDRESS_272525] meet all of the following criteria: 
 
1. Enrolled in NYU CHES study at the NYULH-Brooklyn campus 
2. Over [ADDRESS_272526] 37 weeks gestation or <6 months postpartum 
4. Carrying singleton fetus or having given birth to a singleton infant 
5. Intending to breastfeed or breastfeeding 
6. English or Spanish speaking 
7. Intending to obtain/obtaining pediatric care for infant at the Sunset Park Family Health Center at NYU Langone 
4.2 Exclusion Criteria
An individual who meets any of the following criteria will be excluded from participation in this study:
 
1. Not enrolled in NYU CHES study from the NYULH-Brooklyn campus  
2. Under 37 weeks gestation or having had a preterm birth 
3. Carrying multiples or having given birth to multiples 
4. Not intending to breastfeed or not currently breastfeeding 
5. Not comfortable communicating in English or Spanish 
6. Not intending to obtain/obtaining pediatric care for infant at NYULH Sunset Park Family Health Center  
7. Under [ADDRESS_272527] milk involves no more than minimal risk. Urine will be collected via a bag that gently 
adheres to the skin around the infant’s penis; breast milk will expressed manually by [CONTACT_2299]. Participation in this study is entirely voluntary. 
Participants will be able to withdraw from the study at any time without negative consequences. Our study design is in compliance with all items 
included in 45 CRF part 46.204 (research involving pregnant women or fetuses) and 46.205 (research involving neonates.) Any risk to neonates is 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 14
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 2022expressly in pursuit of benefits that would directly benefit them; i.e. regulation of chemicals in baby [CONTACT_133294]. Furthermore, while this research 
does not hold out the prospect of benefit for the pregnant woman or the fetus, risk to the fetus is not greater than minimal and the purpose of the 
research is the development of important biomedical knowledge that cannot be obtained by [CONTACT_86416]. A pregnant person’s consent will be 
obtained in accord with the informed consent provisions of subpart A. The risk in this study is the least possible for achieving the objectives of the 
research. No inducements, monetary or otherwise, will be offered to terminate a pregnancy. Individuals engaged in the research will have no part 
in any decisions as to the timing, method, or procedures used to terminate a pregnancy. Individuals engaged in the research will have no part in 
determining the viability of a neonate.  
4.[ADDRESS_272528] reviewed the consent materials. Refer to Section 12.3.2 for more information on the consent procedures.  
 
o If potential participants are not eligible and/or do not wish to take part in the study, their PHI (phone number, address, and any 
other PHI) will be discarded at this point.  
 
 In-Person Screening  
o If possible or preferred by [CONTACT_52764], screening may occur in person at the NYULH Brooklyn location. This will be 
coordinated by [CONTACT_464].  
 
o Study staff will give the potential participant a physical copy of the Key Information Sheet and Study Infographic if it has not 
already been sent to them. If the potential participant is interested, study staff will ask screening questions to confirm eligibility.  
 
o If the potential participant is eligible and still interested in learning more about the study, the study staff member will walk the 
potential participant through Informed Consent. If the potential participant wishes to take part in this study, she will be asked to 
sign a paper copy of the Informed Consent. Refer to Section 12.3.[ADDRESS_272529] them again two weeks and six weeks after birth to check in on the diaper delivery 
logistics and assess and encourage group assignment adherence.  
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 15
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July [ZIP_CODE].4.1 Use of DataCore/Epic Information for Recruitment Purposes
 
This study will not use NYULH’s DataCore/Epic information for recruitment purposes. We will use participant information from our ongoing study 
NYU CHES study for recruitment purposes.  
4.[ADDRESS_272530] and with no consequence.  
 
An investigator may terminate participation in the study if: 
 
 Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in 
the study would not be in the best interest of the participant. 
 The participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study 
participation. 
4.7.2 Handling of Participant Withdrawals or Termination
If a participant withdraws between the time of consent and biospecimen collection, the participant will be replaced.  
4.7.3 Premature Termination or Suspension of Study
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. Written notification, documenting the 
reason for study suspension or termination, will be provided by [CONTACT_226737]. If the study is prematurely terminated 
or suspended, the PI [INVESTIGATOR_33894](s) for the termination or suspension. 
 
Circumstances that may warrant termination or suspension include, but are not limited to: 
 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 16
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 2022 PI [INVESTIGATOR_226717]/or IRB. 
 
5 Behavioral/Social Intervention 
5.1 Study Intervention Description
 
The study intervention is supply of baby [CONTACT_133294]. The intervention group (n=5) in this study will be assigned use of phthalate- and bisphenol-free 
baby [CONTACT_226738] a cloth diaper service. Participants assigned to the control group (n=5) will receive disposable diaper delivery 
and conventional baby [CONTACT_133294].  
5.1.1 Administration of Intervention
 
This intervention (supply of baby [CONTACT_133294]) will be delivered via mail and/or delivery service. The frequency of delivery will depend on the delivery 
service. The delivery will cover three months’ worth of diapers and baby [CONTACT_133294].  
6 Study Procedures and Schedule 
6.1 Study Procedures/Evaluations 
6.1.1 Study Specific Procedures
Biospecimen Collection:  
 
 Biospecimens (1.8mL of maternal breast milk, 1.8mL of maternal urine, and 1.8 mL of infant urine) will be collected at one study visit 
approximately 2-3 months after enrollment. Biospecimen collection will occur either after a routine well-visit or at the participant’s home. If 
a home visit occurs, study staff will go to the participant’s home. Refer to Section 6.2 for more details.  
Data Collection:  
 
 Participant’s electronic medical record will be used to monitor when they have delivered. 
 Either the infant’s medical record or the NYU CHES study records will be used to obtain birth weight and length for analysis.  
 NYC CHES study questionnaire data that participants previously completed under the NYU CHES study will be pulled from the NYU 
CHES study database.    
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 17
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 2022 We will create a new database for the Diaper Study where we will store all Diaper Study-related results along with demographic and NYU 
CHES study questionnaire data to be pulled from the NYU CHES database.   
 
Questionnaire Administration:  
 
 Participants will be asked to complete a brief adherence questionnaire at three postpartum time points.  
o Questionnaire will be administered over the phone by [CONTACT_3462] [ADDRESS_272531] milk into a polypropylene specimen cup (Starplex Scientific Corp., Cleveland, TN).  
 
Maternal urine will be collected via standard procedure in a sterile cup.  
 
To collect infant urine, a Pediatric Urine Collector (Precision Dynamics Corp., Valencia, CA) will be provided to participants. This device is 
composed of a clear plastic bag with a foam-lined opening that adheres to the skin around the infant’s genital area without puckering, providing a 
leak-proof seal. 
Diaper Study personnel will not be involved in the maternal specimen collection procedures. Diaper Study personnel will facilitate the collection of 
infant urine.  
6.2.[ADDRESS_272532] milk will be aliquoted into bisphenol- and phthalate-free 2 mL tubes (Thermo Scientific, Waltham, MA) within two hours of 
collection and will be stored at -80oC. Urine and breast milk collection containers/devices will be tested for the presence of phthalates and 
bisphenols. 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023    Page 18
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July [ZIP_CODE].2.3 Specimen Shipment
N/A 
 
6.2.4 Laboratory Evaluations
Chemical analyses. Phthalate metabolites and bisphenols will be analyzed at the NYU Human and Environmental Exposure Assessment Facility 
Core lab under the supervision of Sunmi Lee.  
 
Bisphenols.  Eight bisphenols (BPA, BPAF, BPAP, BPB, BPF, BPP, BPS, and BPZ) will be determined by [CONTACT_5004]-ESI-MS/MS. Concentrations of 
individual bisphenols will be adjusted for creatinine (Cr) as described below. We will also sum molar concentrations of all individual bisphenols for 
a total bisphenol concentration. 
 
Phthalate metabolites. Quantitative detection of 22 phthalate metabolites will also involve HPLC-ESI-MS/MS.22Urine samples will be processed 
using enzymatic deconjugation of glucuronidated phthalate monoesters, followed by [CONTACT_226739]-phase HPLC-ESI-
MS/MS. Individual phthalate metabolite concentrations will be adjusted for Cr as described below. We will also sum metabolites of parent 
compounds di-2-ethylhexyl phthalate (DEHP), as well as di-isononyl phthalate (DiNP) and di- n-octyl phthalate (DNOP), as DiNP, DNOP, and di-
isodecyl phthalate (DiDP, represented by [CONTACT_226740]-carboxyl isononyl phthalate [mCINP]) are increasingly replacing DEHP in response 
to consumer advocacy and legislative activity.23
Creatinine.  To account for urinary dilution, urinary Cr will be analyzed using HPLC-ESI-MS/MS as described elsewhere24and chemical 
concentrations will be adjusted for Cr via a transformation described by [CONTACT_226741].,25with an alternate adjustment method by O’Brien et al.26and 
no adjustment explored in sensitivity analyses. 
6.[ADDRESS_272533]. Refer to Section 4.4 for details.  
6.3.2 Enrollment/Baseline
 Diaper Study team member will obtain consent.  
 Diaper Study team member will assign participant to study group in alternating fashion. Participants will not be told of their group 
assignment in advance of delivery or postpartum consent.  
 Diaper Study team member will obtain participant’s delivery date from participant’s EMR and schedule diaper delivery to their home to 
begin directly afterward or schedule diaper delivery to begin immediately if consent occurs postpartum.  
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 19
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July [ZIP_CODE].3.3 Phone Call - 2 Weeks After Delivery
 
 Diaper Study team member will confirm consent.  
 Participants will complete questionnaire by [CONTACT_648]. 
6.3.4 Phone Call - 6 Weeks After Delivery 
  
Diaper Study team member will confirm consent. 
 Participants will complete questionnaire by [CONTACT_648]. 
6.3.5 Study Visit
 
 After using products in assigned study group for up to three months, a single study visit will occur after a routine well-visit or at 
participant’s home between 2 and 3 months after diaper intervention has begun. If visit cannot occur after infant’s well-visit, Diaper Study 
team member will go to participant’s home. 
 Diaper Study team member will confirm consent.   
 Participants will be asked to provide maternal breast milk and urine samples. 
 Diaper Study team member will collect infant urine sample. 
 Participants will complete questionnaire. 
  
6.3.6 Withdrawal Visit
 No procedures or evaluations will be done and no biospecimens will be collected if a participant withdraws or is terminated early.  
6.3.7 Unscheduled Visit 
 We do not anticipate unscheduled visits. 
 
 
7 Safety and Adverse Events 
7.1 Definition of Adverse Events (AE)
An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in severity during the course of the study.  
Intercurrent illnesses or injuries should be regarded as adverse events.  Abnormal results of diagnostic procedures are considered to be adverse 
events if the abnormality: 
 results in study withdrawal 
 is associated with a serious adverse event 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 20
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 2022 is associated with clinical signs or symptoms 
 leads to additional treatment or to further diagnostic tests 
 is considered by [CONTACT_1372] 
7.1.1 Definition of Serious Adverse Events (SAE)
 
Serious Adverse Event 
Adverse events are classified as serious or non-serious.  A serious adverse event  is any AE that is:  
 fatal 
 life-threatening 
 requires or prolongs hospi[INVESTIGATOR_226718] 
 a congenital anomaly or birth defect 
 an important medical event 
 
Important medical events are those that may not be immediately life threatening, but are clearly of major clinical significance. They may jeopardize 
the subject, and may require intervention to prevent one of the other serious outcomes noted above.  For example, drug overdose or abuse, a 
seizure that did not result in in-patient hospi[INVESTIGATOR_059], or intensive treatment of bronchospasm in an emergency department would typi[INVESTIGATOR_48517].  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non-serious adverse events .  
7.1.2 Definition of Unanticipated Problems (UP)
 
Unanticipated Problems Involving Risk to Subjects or Others 
Any incident, experience, or outcome that meets all of the following criteria:  
Unexpected in nature, severity, or frequency (i.e. not described in study-related documents such as the IRB-approved protocol or consent 
form, the investigators brochure, etc.)
 Related or possibly related to participation in the research (i.e. possibly related means there is a reasonable possibility that the incident 
experience, or outcome may have been caused by [CONTACT_3459])
 Suggests that the research places subjects or others at greater risk of harm (including physical, psychological, economic, or social harm). 
7.2 Classification of an Adverse Event
7.2.1 Severity of Event
For AEs not included in the protocol defined grading system, the following guidelines will be used to describe severity.
 
 Mild – Events require minimal or no treatment and do not interfere with the participant’s daily activities. 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 21
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 2022 Moderate  – Events result in a low level of inconvenience or concern with the therapeutic measures. Moderate events may cause some 
interference with functioning. 
 Severe – Events interrupt a participant’s usual daily activity and may require systemic drug therapy or other treatment. Severe events are 
usually potentially life-threatening or incapacitating. 
 
7.2.2 Relationship to Study Intervention
 
The clinician’s assessment of an AE's relationship to study intervention is part of the documentation process, but it is not a factor in determining 
what is or is not reported in the study. If there is any doubt as to whether a clinical observation is an AE, the event should be reported. All AEs 
must have their relationship to study intervention assessed. In a clinical trial, the study intervention must always be suspect. To help assess, the 
following guidelines are used. 
 
 Related – The AE is known to occur with the study intervention, there is a reasonable possibility that the study intervention caused the AE, 
or there is a temporal relationship between the study intervention and event. Reasonable possibility means that there is evidence to 
suggest a causal relationship between the study intervention and the AE. 
 
 Not Related  – There is not a reasonable possibility that the administration of the study intervention caused the event, there is no temporal 
relationship between the study intervention and event onset, or an alternate etiology has been established. 
7.2.[ADDRESS_272534], systematic format using a grading scale based on functional assessment or magnitude of reaction. Describe the method of determining 
the expectedness of an AE. Expectedness refers to the awareness of AEs previously observed, not on the basis of what might be anticipated from 
the properties of the study intervention. 
7.3 Time Period and Frequency for Event Assessment and Follow-Up
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and interviews of a study participant presenting 
for medical care, or upon review by a study monitor. All AEs including local and systemic reactions not meeting the criteria for SAEs will be 
captured on the appropriate RF. Information to be collected includes event description, time of onset, clinician’s assessment of severity, 
relationship to study intervention (assessed only by [CONTACT_8703] a diagnosis), and time of resolution/stabilization 
of the event. All AEs occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed to adequate 
resolution. 
 
Any medical condition that is present at the time that the participant is screened will be considered as baseline and not reported as an AE. 
However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in the data 
collection system throughout the study. 
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. 
AEs characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865]. 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 22
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: [ADDRESS_272535] all reportable events with start dates occurring any time after informed consent is obtained until 7 (for non-serious AEs) or 30 
days (for SAEs) after the last day of study participation. At each study visit, the investigator will inquire about the occurrence of AE/SAEs since the 
last visit. Events will be followed for outcome information until resolution or stabilization.  
 
All unresolved adverse events should be followed by [CONTACT_1374], the subject is lost to follow-up, or the adverse 
event is otherwise explained.  At the last scheduled visit, the investigator should instruct each subject to report any subsequent event(s) that the 
subject, or the subject’s personal physician, believes might reasonably be related to participation in this study.  The investigator should notify the 
study sponsor of any death or adverse event occurring at any time after a subject has discontinued or terminated study participation that may 
reasonably be related to this study. 
7.4 Reporting Procedures – Notifying the IRB 
7.4.[ADDRESS_272536] be followed up to determine the final outcome.  Any serious adverse event that occurs after the study period 
and is considered to be possibly related to study participation should be recorded and reported immediately. 
 
7.4.2 Serious Adverse Event Reporting
If the report is supplied as a narrative, the minimum necessary information to be provided at the time of the initial report includes:
 Study identifier 
 Study Center 
 Subject number 
 A description of the event 
Date of onsetCurrent status
 Whether study treatment was discontinued 
 The reason why the event is classified as serious 
 Investigator assessment of the association 
between the event and study treatment 
7.4.3 Unanticipated Problem Reporting
Incidents or events that meet the OHRP criteria for UPs require the creation and completion of an UP report form. It is the site investigator’s 
responsibility to report UPs to their IRB and to the DCC/study sponsor. The UP report will include the following information: 
 
 Protocol identifying information: protocol title and number, PI’s name, and the IRB project number; 
 A detailed description of the event, incident, experience, or outcome; 
 An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP; 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 23
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: [ADDRESS_272537] been taken or are proposed in response to the UP. 
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline: 
 
 UPs that are SAEs will be reported to the IRB and to the DCC/study sponsor within <insert timeline in accordance with policy> of the 
investigator becoming aware of the event. 
 Any other UP will be reported to the IRB and to the DCC/study sponsor within <insert timeline in accordance with policy> of the investigator 
becoming aware of the problem. 
 All UPs should be reported to appropriate institutional officials (as required by [CONTACT_17347]’s written reporting procedures), the supporting 
agency head (or designee), and OHRP within<insert timeline in accordance with policy> of the IR’s receipt of the report of the problem from 
the investigator. 
 
7.4.4 Reporting of Pregnancy
N/A 
7.5 Reporting Procedures – Notifying the Study Sponsor 
N.A 
7.6 Reporting Procedures – Participating Investigators 
N/A
 
[ADDRESS_272538]. Linda Kahn, and communicate with staff to ensure adequate risk 
assessment, adverse event reporting, compliance with protocol, and drop-out rates, with monthly review of safety data and appropriate reporting 
requirements to the NYU Langone Health IRB. Should unanticipated reportable events, defined as internal or external events (such as deaths, life-
threatening experiences, injuries, breaches of confidentiality, or other problems), occur at any time during or after the research study, [CONTACT_226752] will 
report them immediately to the NYU Grossman School of Medicine IRB. Any new information indicating a change to the risks or potential benefits 
of the research, any deviation from the protocol, and any possible serious or continued non-compliance will be reported to the NYU Langone 
Health IRB by [INVESTIGATOR_124]. Kahn immediately. 
 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 24
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July [ZIP_CODE] Statistical Considerations 
9.1 Statistical and Analytical Plans
There will not be a formal SAP in this study, as it is a pi[INVESTIGATOR_226719] 10 participants. Demographics will be compared between members of the 
intervention and control groups to assess the success of the randomization process.  T-tests will be used to compare phthalate metabolite and 
bisphenol levels between the two groups and correlations of chemical levels will be run comparing mothers and infants in the control group. 
9.2 Statistical Hypotheses 
Aim 1: H1: We will successfully recruit participants from within an existing cohort study and collect biosamples from participants and their children 
in a single follow-up study visit.  
 
Aim 2: Chemical levels will be higher among infants in the control group vs. the intervention group. There will be no difference in average chemical 
concentrations between the two groups of mothers. Among controls, different chemicals will be present in breast milk vs. infant urine. 
9.3 Analysis Datasets
We will perform both ITT analysis as well as Per-Protocol Analysis, based on participants’ self-reported compliance, which will be assessed 
periodically throughout the intervention. 
9.4 Description of Statistical Methods
9.4.1 Analysis of the Primary Efficacy Endpoint
Our primary aim is to assess the feasibility of the intervention. There are no relevant statistical endpoints. 
9.4.2 Analysis of the Secondary Endpoints
Our secondary endpoints are concentrations of bisphenols and phthalate metabolites in breastmilk and infant urine. We will perform t-tests to 
compare distributions of chemicals between the two infant groups to assess the effectiveness of the intervention. We will also assess correlations 
of concentrations of individual bisphenols and phthalate metabolites between mothers and children from the control group to assess the relative 
prevalence of these chemicals in diet (measured in maternal breast milk) vs. baby [CONTACT_133294] (infant urine).  
9.4.3 Safety Analyses
There is no risk associated with the intervention being implemented in this study, so there will be no safety analysis.
9.4.4 Adherence and Retention Analyses
We will calculate the percent of participants that complete the study as well as the average adherence to protocol in each of the two arms based 
on participant self-report. 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 25
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July [ZIP_CODE].4.5 Baseline Descriptive Statistics
T-tests and chi-square tests (as appropriate) will be used to assess differences in demographic characteristics between participants in the 
intervention and control groups.  
 
Because this is a pi[INVESTIGATOR_123712], it is not adequately powered to detect statistically significant associations or to permit controlling for covariates or 
multiple comparisons. The sample size (10 total; 5 per group) has been determined based on budgetary considerations. 
9.4.6 Enrollment/Randomization/Masking Procedures
Participants will be assigned to either the intervention or control group on an alternating basis upon enrollment. Because of the nature of the 
intervention (cloth vs. conventional diapers), they will not be blinded. If a participant needs to be replaced, the replacement will be assigned to the 
same group as the participant who withdrew.  
9.4.7 Evaluation of Success of Blinding
N/A 
9.4.8 Breaking the Study Blind/Participant Code
N/A 
 
10 Source Documents and Access to Source Data/Documents 
Source data is all information, original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction 
and evaluation of the trial.  Source data are contained in source documents.  Examples of these original documents, and data records include: 
hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, 
recorded data from automated instruments, copi[INVESTIGATOR_10379], microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories, and at medico-
technical departments involved in the clinical trial.  
 
The study case report form (CRF) is the primary data collection instrument for the study.  All data requested on the CRF must be recorded.  All 
missing data must be explained.  If a space on the CRF is left blank because the procedure was not done or the question was not asked, write 
“N/D”.  If the item is not applicable to the individual case, write “N/A”.  All entries should be printed legibly in black ink.  If any entry error has been 
made, to correct such an error, draw a single straight line through the incorrect entry and enter the correct data above it.  All such changes must 
be initialed and dated.  DO NOT ERASE OR WHITE OUT ERRORS.  For clarification of illegible or uncertain entries, print the clarification above 
the item, then initial and date it. 
 
Access to study records will be limited to IRB-approved members of the study team. The investigator will permit study-related monitoring, audits, 
and inspections by [CONTACT_1201]/EC, the sponsor, government regulatory bodies, and University compliance and quality assurance groups of all study 
related documents (e.g. source documents, regulatory documents, data collection instruments, study data etc.).  The investigator will ensure the 
capability for inspections of applicable study-related facilities (e.g. pharmacy, diagnostic laboratory, etc.). 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 26
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 2022 
Participants who consent to this study are already enrolled in NYU CHES Study, and are also consenting to allowing their data to be shared 
between the Diaper Study and NYU CHES Study. Examples of data that can be shared between the two studies include biospecimen and 
questionnaire responses.  
 
Participation as an investigator in this study implies acceptance of potential inspection by [CONTACT_226742]. 
 
11 Quality Assurance and Quality Control
 
Bisphenols. Eight bisphenols (BPA, BPAF, BPAP, BPB, BPF, BPP, BPS, and BPZ) will be determined by [CONTACT_5004]-ESI-MS/MS. In our experience 
with Sunmi Lee’s laboratory, coefficients of variation are minimal/good for bisphenols (1–15%). With the use of isotopi[INVESTIGATOR_226720], limits of detection (LODs) measured in a recent NYU CHES sample ranged from 0.04-0.50 ng/mL, sufficient for measuring urinary 
bisphenols in non-occupationally exposed subjects.27 Calibration checks as well as method control and fortified samples ensure results are within 
±15% of the nominal value, with duplicates performed within each batch to ensure precision within ±15%.  
 
Phthalate metabolites. Quantitative detection of 22 phthalate metabolites will also involve HPLC-ESI-MS/MS.22Urine samples will be processed 
using enzymatic deconjugation of glucuronidated phthalate monoesters, followed by [CONTACT_226739]-phase HPLC-ESI-
MS/MS. Coefficients of variation from samples analyzed in Sunmi Lee’s laboratory are minimal/good for phthalates (1–15%); LODs measured in a 
recent NYU CHES sample ranged from 0.02–0.74 ng/mL. Calibration checks as well as method control and fortified samples ensure results are 
within ±15% of the nominal value, with duplicates performed within each batch to ensure precision within ±15%.  
 
12 Ethics/Protection of Human Subjects 
12.[ADDRESS_272539]
The protocol, key information sheet(s), informed consent form(s), recruitment materials, and all participant materials will be submitted to the IRB 
for review and approval. IRB approval will be obtained before any participant is enrolled in this study. Any amendment to the protocol will require 
review and approval by [CONTACT_3484]. All changes to the consent materials will be IRB approved; a 
determination will be made regarding whether previously consented participants need to be re-consented. 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 27
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 202212.3 Informed Consent Process 
12.3.1 Consent and Other Informational Documents Provided to Participants
 
Consent materials describing in detail the study purpose, study procedures, and potential risks are given to the participant and written 
documentation of informed consent is required prior to starting the study protocol. The following consent materials are submitted with this protocol: 
 
 Key information sheet (English) 
 Consent document for mother and infant (English) 
 Participation timeline infographic (English)  
 Contact [CONTACT_226743] a Modification at a later time.  
12.3.2 Consent Procedures and Documentation 
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and continues throughout the individual’s 
study participation. Extensive description of risks and possible benefits of participation will be provided to the participants. Consent materials will 
be IRB-approved and potential participants will be asked to read and review the consent documents, which will be either emailed to them or 
handed to them physically, as described in section 4.4.  
An IRB-approved Diaper Study team member will begin the informed consent process with a concise and focused presentation of the key 
information using an IRB-approved Key Information Sheet . If potential participant is interested in learning more about this study, she will have her 
eligibility assessed by [CONTACT_464]. If potential participant is eligible and interested, the study team member will fully explain the research study 
using the IRB-approved Informed Consent  template as the consent script and answer any questions that may arise.  
 
All participants will receive a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks of the 
study and of their rights as research participants. Participants will have the opportunity to carefully review the written consent form, ask questions, 
and discuss the study with their family members, friends, or doctor prior to signing or providing verbal consent. The rights and welfare of the 
participants will be protected by [CONTACT_38077]. 
 
If potential participant is eligible and would like to take part in this study, and the informed consent process takes place in person: 
 
 Individual will be asked to sign a paper copy of the Informed Consent. 
 
If potential participant is eligible and would like to take part in this study, the informed consent process takes place remotely (by [CONTACT_648]), and the 
individual has the ability to provide an electronic signature:  
 
[CONTACT_226750]: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 28
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 2022 Individual will be asked to sign the electronic consent (eConsent) via REDCap. The REDCap eConsent link will be submitted to the IRB for 
review in Research Navigator via Modification before use in the study. Language consistency with the IRB-approved consent will be 
reviewed and approved by [CONTACT_112392].  
 
If potential participant is eligible and would like to take part in this study, the informed consent process takes place remotely (by [CONTACT_648]), but the 
individual does not have the technical ability to provide an electronic signature: 
 
 [CONTACT_226751]. The 
staff member will record this in the participant record on REDCap. The participant will sign the printed consent form at the earliest 
opportunity (e.g., her next prenatal visit, in the hospi[INVESTIGATOR_226721], etc.) before any biospecimens are collected. 
 
At the time of consent, participant will also provide consent for her future child’s participation. A copy of the signed informed consent document will 
be given to the participants for their records either at the time of consent if screening and consent takes place in person or at the earliest possible 
in-person encounter, which is when those providing verbal consent will sign a physical copy of the form and those who eConsented will receive a 
printout of their signed eConsent form. A copy of the signed informed consent document will be stored in the participant’s research record. The 
consent process, including the name [CONTACT_21811], will be thoroughly documented in the subject’s research record. Any 
alteration to the standard consent process (e.g., use of a translator, consent document presented orally, etc.) and the justification for such 
alteration will likewise be documented.  
12.[ADDRESS_272540] of 1996 (HIPAA).  Those regulations require a signed subject authorization informing the subject of the following:  
 
 What protected health information (PHI) will be collected from subjects in this study 
 Who will have access to that information and why 
 Who will use or disclose that information  
 The rights of a research subject to revoke their authorization for use of their PHI.  
In the event that a subject revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains the ability to use all information 
collected prior to the revocation of subject authorization.  For subjects that have revoked authorization to collect or use PHI, attempts should be 
made to obtain permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study period. 
Participant confidentiality will be strictly held in trust by [CONTACT_3486], their staff, and the sponsor(s) and their agents. This 
confidentiality is extended to cover testing of biological samples and genetic tests in addition to the clinical information relating to participants. 
Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning 
the study or the data will be released to any unauthorized third party without prior written approval of the sponsor. 
 
The study monitor, other authorized representatives of the sponsor, or representatives of the IRB may inspect all documents and records required 
to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the 
participants in this study. The clinical study site will permit access to such records. 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 29
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 2022 
The study participant’s contact [CONTACT_226744]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_226745]. 
 
All raw data gathered for the study will be kept in a locked cabinet in the Division of Environmental Pediatrics. All computerized data files will be 
maintained on a password-protected computer system on both NYULH MCIT-managed network shared drive set up for this study and on REDCap 
and will only be accessible to trained study personnel. All participants will be assigned a unique identifier (code number) that will be used in all 
computerized files containing study data. A file containing links between participant identity and code number will be maintained in a separate file 
with a separate password and will only be accessible to trained study personnel who must know the participants’ identities to contact [CONTACT_226746], to schedule appointments, to conduct follow-up calls, and/or to manage the data. All study personnel will receive training in human 
subjects’ protection prior to any involvement with participants or study data and will be continuously supervised by [INVESTIGATOR_124]. Kahn. 
 
This study will not affect treatment or determine prognosis for an individual participant. Data and samples collected in the study are being used for 
research purposes only. The results from this study will not be shared with participants’ medical providers. Participants will not receive the results 
of their chemical analysis.  
 
To further protect the privacy of study participants, a Certificate of Confidentiality will be obtained from the NIH. This certificate protects identifiable 
research information from forced disclosure. It allows the investigator and others who have access to research records to refuse to disclose 
identifying information on research participation in any civil, criminal, administrative, legislative, or other proceeding, whether at the federal, state, 
or local level. By [CONTACT_175319], 
Certificates of Confidentiality help achieve the research objectives and promote participation in studies by [CONTACT_4205][INVESTIGATOR_52572]. 
12.4.[ADDRESS_272541]. Trasande. This research biobank is being created so that researchers in the Division of 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 30
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: [ADDRESS_272542] information of all involved investigators, study personnel, and source of funding.  
 
 Researchers from outside institutions carrying out specific research that is not contrary to NYU Langone policies and scientists from 
industry will also be considered. Transfers of Human Biospecimens to outside institutions require a duly authorized agreement between 
NYU/NYU Langone and the recipi[INVESTIGATOR_226722]. 
 
 Requests for use of data or stored biospecimens for scientific purposes will be considered by a committee chaired by [INVESTIGATOR_124]. Kahn, the PI [INVESTIGATOR_226723], that includes faculty with relevant experience 
 
[ADDRESS_272543] protection and internal quality checks, 
such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the 
source 
13.2 Study Records Retention
Study documents will be retained for the longer of 3 years after close out or 5 years after final reporting/publication. No records will be destroyed 
without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no 
longer need to be retained. 
13.3 Protocol Deviations
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 31
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: [ADDRESS_272544]: Anna Carrasco ([EMAIL_4480]) 
[ADDRESS_272545] 
[PHONE_4800] 
14.2 Costs to the Participant
We do not anticipate any costs to the participant in this study.  
14.3 Participant Reimbursements or Payments
Participants in this study will receive no reimbursements or payments. 
15 Study Administration
15.1 Study Leadership
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 32
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: [ADDRESS_272546]. Kahn’s Sub-Investigator, providing 
expertise in quantifying phthalate metabolites and bisphenols in human biosamples. This study will also be supervised by [INVESTIGATOR_60055]-I [CONTACT_226753], 
the PI [INVESTIGATOR_226724]. 
 
[ADDRESS_272547] with this study (patent ownership, royalties, or financial gain greater than the minimum allowable by 
[CONTACT_1385], etc.) must have the conflict reviewed by [CONTACT_21804] a Committee-sanctioned conflict 
management plan that has been reviewed and approved by [CONTACT_28833]. All NYULH investigators will 
follow the applicable conflict of interest policies. 
17 References
1. Barker DJ. The origins of the developmental origins theory. Journal of internal medicine . May 2007;261(5):412-7. doi:10.1111/j.1365-
2796.2007.[ZIP_CODE].x 
2. Braun JM. Early-life exposure to EDCs: role in childhood obesity and neurodevelopment. Nature reviews Endocrinology . Mar 
2017;13(3):161-173. doi:10.1038/nrendo.2016.186 
3. Kahn LG, Philippat C, Nakayama SF, Slama R, Trasande L. Endocrine-disrupting chemicals: implications for human health. Lancet 
Diabetes Endocrinol . 2020;8(8):703-718.  
4. Becker M, Hesse V. Minipuberty: Why Does it Happen? Hormone research in paediatrics . 2020;93(2):76-84. doi:10.1159/000508329 
5. Skakkebaek NE, Rajpert-De Meyts E, Buck Louis GM, et al. Male Reproductive Disorders and Fertility Trends: Influences of Environment 
and Genetic Susceptibility. Physiological reviews . Jan 2016;96(1):55-97. doi:10.1152/physrev.[ZIP_CODE].2015 
6. Prince FP. The triphasic nature of Leydig cell development in humans, and comments on nomenclature. The Journal of endocrinology . 
Feb 2001;168(2):213-6. doi:10.1677/joe.0.1680213 
7. Sarraj MA, Drummond AE. Mammalian foetal ovarian development: consequences for health and disease. Reproduction (Cambridge, 
England) . Feb 2012;143(2):151-63. doi:10.1530/rep-11-0247 
8. Kuiri-Hänninen T, Kallio S, Seuri R, et al. Postnatal developmental changes in the pi[INVESTIGATOR_2117]-ovarian axis in preterm and term infant girls. 
The Journal of clinical endocrinology and metabolism . Nov 2011;96(11):3432-9. doi:10.1210/jc.2011-1502 
9. Wang H, Liu L, Wang J, et al. Urinary sexual steroids associated with bisphenol A (BPA) exposure in the early infant stage: Preliminary 
results from a Daishan birth cohort. The Science of the total environment . Dec 1 2017;601-602:1733-1742. doi:10.1016/j.scitotenv.2017.05.257 
10. Friederici AD, Pannekamp A, Partsch CJ, et al. Sex hormone testosterone affects language organization in the infant brain. Neuroreport . 
Feb 12 2008;19(3):283-6. doi:10.1097/WNR.0b013e3282f5105a 
11. Beech JR, Beauvois MW. Early experience of sex hormones as a predictor of reading, phonology, and auditory perception. Brain and 
language . Jan 2006;96(1):49-58. doi:10.1016/j.bandl.2005.08.006 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 33
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: 18 July 202212. Hines M, Spencer D, Kung KT, Browne WV, Constantinescu M, Noorderhaven RM. The early postnatal period, mini-puberty, provides a 
window on the role of testosterone in human neurobehavioural development. Current opi[INVESTIGATOR_33591] . Jun 2016;38:69-73. 
doi:10.1016/j.conb.2016.02.008 
13. Kung KT, Browne WV, Constantinescu M, Noorderhaven RM, Hines M. Early postnatal testosterone predicts sex-related differences in 
early expressive vocabulary. Psychoneuroendocrinology . Jun 2016;68:111-6. doi:10.1016/j.psyneuen.2016.03.001 
14. Lamminmäki A, Hines M, Kuiri-Hänninen T, Kilpeläinen L, Dunkel L, Sankilampi U. Testosterone measured in infancy predicts subsequent 
sex-typed behavior in boys and in girls. Hormones and behavior . Apr 2012;61(4):611-6. doi:10.1016/j.yhbeh.2012.02.013 
15. Becker M, Oehler K, Partsch CJ, et al. Hormonal 'minipuberty' influences the somatic development of boys but not of girls up to the age of 
6 years. Clinical endocrinology . Nov 2015;83(5):694-701. doi:10.1111/cen.[ZIP_CODE] 
16. Makos-Chelstowska P, Kurowska-Susdorf A, Plotka-Wasylka J. Environmental problems and health risks with disposable baby [CONTACT_226747]: 
Monitoring of toxic compounds by [CONTACT_226748]. Trends in Analytic Chemistry . 2021;143 
17. Park CJ, Barakat R, Ulanov A, et al. Sanitary pads and diapers contain higher phthalate contents than those in common commercial 
plastic products. Reproductive toxicology (Elmsford, NY) . Mar 2019;84:114-121. doi:10.1016/j.reprotox.2019.01.005 
18. Sathyanarayana S, Karr CJ, Lozano P, et al. Baby [CONTACT_226749]: possible sources of infant phthalate exposure. Pediatrics . Feb 
2008;121(2):e260-8. doi:10.1542/peds.2006-3766 
19. Li D, Shi Y, Yang L, et al. Microplastic release from the degradation of polypropylene feeding bottles during infant formula preparation. 
Nature Food . 2020;1:746-754.  
20. Environmental Health Criteria 235: Dermal Absorption (International Programme on Chemical Safety (IPCS)) (2006). 
21. Kannan K, Stathis A, Mazzella MJ, et al. Quality assurance and harmonization for targeted biomonitoring measurements of environmental 
organic chemicals across the Children's Health Exposure Analysis Resource laboratory network. International journal of hygiene and 
environmental health . May 2021;234:113741. doi:10.1016/j.ijheh.2021.113741 
22. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-
2004. Environmental health perspectives . Jan 2008;116(1):39-44. doi:10.1289/ehp.[ZIP_CODE] 
23. Silva MJ, Samandar E, Preau JL, Jr., Reidy JA, Needham LL, Calafat AM. Quantification of 22 phthalate metabolites in human urine. 
Journal of chromatography B, Analytical technologies in the biomedical and life sciences . Dec 1 2007;860(1):106-12. 
doi:10.1016/j.jchromb.2007.10.023 
24. Zota AR, Calafat AM, Woodruff TJ. Temporal trends in phthalate exposures: findings from the National Health and Nutrition Examination 
Survey, 2001-2010. Environmental health perspectives . Mar 2014;122(3):235-41. doi:10.1289/ehp.1306681 
25. Zhang Z, Alomirah H, Cho HS, et al. Urinary bisphenol A concentrations and their implications for human exposure in several Asian 
countries. Environmental science & technology . Aug 15 2011;45(16):7044-50. doi:10.1021/es200976k 
26. Kuiper JR, O'Brien KM, Ferguson KK, Buckley JP. Urinary specific gravity measures in the U.S. population: Implications for the adjustment 
of non-persistent chemical urinary biomarker data. Environ Int . Nov 2021;156:106656. doi:10.1016/j.envint.2021.106656 
27. O'Brien KM, Upson K, Cook NR, Weinberg CR. Environmental Chemicals in Urine and Blood: Improving Methods for Creatinine and Lipid 
Adjustment. Environmental health perspectives . Feb 2016;124(2):220-7. doi:10.1289/ehp.1509693 
18 Attachments
These documents are relevant to the protocol, but they are not considered part of the protocol.  They are stored and modified separately. As such, 
modifications to these documents may not require protocol amendments. 
 
 Adherence survey 
 Recruitment script 
Study Number: s23-[ZIP_CODE] 
Version Date: 12/06/2023   Page 34
CONFIDENTIAL
This material is the property of the NYU Langone Health.  Do not disclose or use except as authorized in writing by [CONTACT_226727]: [ADDRESS_272548] for participants  
 